<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-017-0201-6">https://link.springer.com/article/10.1007/s13555-017-0201-6</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/âmailto:adisrapidplus@springer.comâ"><b>adisrapidplus@springer.com</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer revi...
<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a hre...
Purpose: This article aims to review the etiology of atopic dermatitis and the biologics class of m...
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to s...
Objective: The objective of this selective EBM review is to determine whether or not dupilumab is a ...
Article full text The full text of this article can be found here. Provide enhanced digital featu...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
We have read with great interest the article by Kreeshan et al., which reported data on effectivenes...
Dupilumab is the first biologic approved for the treatment of patients with moderate-to-severe atopi...
Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly...
Background: Significant unmet need exists for long-term treatment of moderate to severe atopic derma...
<p></p><p><b>Article full text</b></p><p><br></p><p>The full text of this article can be found here<...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a hre...
Purpose: This article aims to review the etiology of atopic dermatitis and the biologics class of m...
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to s...
Objective: The objective of this selective EBM review is to determine whether or not dupilumab is a ...
Article full text The full text of this article can be found here. Provide enhanced digital featu...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
We have read with great interest the article by Kreeshan et al., which reported data on effectivenes...
Dupilumab is the first biologic approved for the treatment of patients with moderate-to-severe atopi...
Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly...
Background: Significant unmet need exists for long-term treatment of moderate to severe atopic derma...
<p></p><p><b>Article full text</b></p><p><br></p><p>The full text of this article can be found here<...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a hre...
Purpose: This article aims to review the etiology of atopic dermatitis and the biologics class of m...
© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of...